Interpace Biosciences, Inc. (OTCQX: IDXG) announced its financial results for the fourth quarter and full year ended December 31, 2025, showcasing a robust performance driven by its focus on thyroid diagnostics. The company reported fourth quarter revenue of $9.2 million, a notable increase from the previous year, and full year revenue of $38.7 million, reflecting a year-over-year growth of 17%. The income from continuing operations for Q4 was reported at $22.8 million, significantly benefiting from a one-time, non-cash tax-related accounting adjustment. This adjustment contributed to a full year income from continuing operations of $25.0 million, compared to $6.9 million in the prior year.

The company highlighted a year-over-year increase in thyroid test volume of 11% for Q4 and 13% for the full year, with thyroid revenue increasing by 14% in Q4 and 21% for the full year. Chris McCarthy, Chief Financial Officer, emphasized the strong performance of the ThyGeNEXT® and ThyraMIR®v2 platforms, which have been pivotal in driving growth. The company also reported a significant improvement in operational efficiency, with a 19% decrease in days sales outstanding (DSO) and a 20% reduction in turnaround time.

Looking ahead, Interpace is positioned to accelerate its growth trajectory in 2026, focusing on scaling thyroid test volume and enhancing operational productivity through automation. The company aims to achieve approximately 16% year-over-year thyroid revenue growth, reflecting its commitment to delivering value to its stakeholders. Overall, the results indicate a strong operational execution and a positive outlook for the company’s strategic initiatives in the thyroid diagnostics market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.